Is ipamorelin really the 'cleanest' or safest GHRP?

Ipamorelin is genuinely the most selective GHRP: in the 1998 discovery study it released growth hormone as potently as GHRP-6 but did not significantly raise cortisol, ACTH, or prolactin, and it stimulates appetite far less. That makes it 'cleaner' on the off-target axes that people dislike about GHRP-6 and GHRP-2. But 'cleaner' is a comparison, not a safety guarantee — it still carries the shared growth-hormone-axis effects (water retention, tingling, joint aches), and like every research peptide it has no validated human safety data.

Does ipamorelin cause water retention?

It can. Mild water retention was reported by 9% of our community users and is tagged moderate. It is the most characteristic growth-hormone effect on the list: raising GH causes the body to hold fluid, showing up as mild puffiness in the hands, ankles, or face and a small water-weight bump. It is the same fluid-retention effect listed on recombinant GH (somatropin) labels, usually milder at peptide doses, tends to be dose-dependent, and often eases if the dose is lowered. It can be amplified when ipamorelin is stacked with CJC-1295.

Why does ipamorelin cause tingling or numbness?

The numbness or tingling reported by 8% of our users usually comes from the water retention, not from the peptide acting on nerves directly. When growth-hormone-driven fluid accumulates, it can press on nerves — a carpal-tunnel-like tingling in the hands and fingers. On GH therapy this is a recognized, usually transient and dose-dependent class effect, so easing the dose tends to settle it. Persistent or worsening numbness is a reason to stop and check with a clinician.

Does ipamorelin increase appetite like other GHRPs?

Far less. Older GHRPs such as GHRP-6 are strong ghrelin-receptor agonists and famously trigger intense hunger; ipamorelin's selectivity means it does this much less, which is why increased hunger sits low on our list at 6%. That is a genuine tolerability advantage for using a GH peptide while managing body composition — but 'milder than GHRP-6' is not 'none,' and some users still notice a mild, dose-related appetite bump.

Are the side effects worse when ipamorelin is stacked with CJC-1295?

They can be additive. CJC-1295 raises growth hormone through a different lever (a longer, stronger GHRH signal), so pairing it with ipamorelin pushes the shared GH-axis effects — especially water retention, and the fluid-related tingling and joint aches — higher than either alone. The selectivity advantages of ipamorelin (low cortisol, prolactin, hunger) still apply, but the GH-driven cluster is the part most likely to intensify on the stack.

A single small clear glass vial of fine white lyophilized peptide powder on a cool-grey laboratory bench beside a sterile unbranded fine-gauge syringe and an amber vial of bacteriostatic water under soft studio lighting.

Ipamorelin Side Effects: The 'Cleanest' GHRP — But Not Side-Effect-Free (2026)

Q: Is ipamorelin safe long-term?

Unknown. There is no published study following people on ipamorelin for months or years, so chronic and delayed effects are simply unmeasured. The main theoretical concern is GH excess: chronically raising growth hormone is what drives acromegaly's problems — insulin resistance, higher blood glucose, and over years acromegaly-like tissue changes. The pulses a peptide produces are smaller, but no one has measured chronic supraphysiologic GHRP use in people, so the community convention is defined cycles rather than open-ended use.

Q: Is ipamorelin FDA-approved or legal?

It is not FDA-approved for any condition and is sold only 'for research use only.' Its furthest development was a Phase 2 trial for postoperative ileus that was discontinued for lack of efficacy. The FDA placed it in 503A compounding Category 2 ('significant safety risks') in September 2023 and removed it in September 2024 after the nomination was withdrawn — a regulatory decision, not proof of safety. As a growth-hormone secretagogue it is also banned in sport (WADA class S2) and will cause a positive drug test for tested athletes.

Prof. Joanna Trylska, Ph.D.Reviewed by Aurélie Rondon, Ph.D.

Updated 2026-06-18T00:00:00.000Z20 min read · 5,261 words

Ipamorelin is widely described as the "cleanest" growth-hormone-releasing peptide — it triggers a GH pulse with far less of the appetite spike, cortisol, and prolactin that older GHRPs like GHRP-6 and hexarelin cause — and our community does report it as well-tolerated, led by a mild injection-site reaction and a brief head-rush. But the honest headline is bigger than that comparison: "cleaner than other GHRPs" is not the same as "safe." Ipamorelin still carries the growth-hormone-axis cluster (mild water retention, tingling, joint aches), and like every research peptide it has never been through a human safety trial, so there is no validated incidence for any of these effects. This page answers the real tolerability question two ways at once: what 450 ProtocolPlus users report from real use, held honestly against how little is actually proven.

Most "ipamorelin side effects" pages are clinic or vendor copy that repeats "selective, no cortisol, no hunger" without a single citation. We do it differently. The headline below is first-party community data — what 450 ProtocolPlus users who tracked ipamorelin tolerability actually report — and we keep two caveats right beside it: the "cleaner GHRP" claim traces to a real 1998 selectivity study, and the absence of validated human incidence is real too. For the molecule itself (what it is, how it works, what it is studied for), this page links up to the Ipamorelin complete guide so it stays a clean safety-and-tolerability hub, and for where ipamorelin sits among the best peptides for muscle growth see that roundup.

Key Takeaways

Anecdotally well-tolerated (what our users report, N=450): the most-reported effect is a mild injection-site reaction (14%, 63 users), then a head-rush or flushing (10%, 45), mild water retention (9%, 40, tagged moderate), numbness/tingling (8%, 36, moderate), headache (8%, 36), and a notably milder increase in hunger (6%, 27) than older GHRPs cause. In our dataset every reported effect was mild or moderate — zero were severe.

The "cleanest GHRP" reputation is real, but it's a comparison. In the 1998 discovery study ipamorelin released GH as potently as GHRP-6 yet, unlike GHRP-6/GHRP-2, did not significantly raise ACTH, cortisol, or prolactin, and it stimulates appetite far less. That is why the hunger column is small here — but "less than GHRP-6" is not "none," and it says nothing about long-term safety.

It still carries the GH-axis cluster. Mild water retention, tingling/paresthesia, and joint aches are the recognized fluid-retention effects of raising growth hormone — the same class effects listed on every somatropin (GH) label — just usually milder at the GH pulses these peptides produce.

"Few reported problems" is NOT proof of safety. Ipamorelin has no completed human safety trials, so there is no validated incidence for any of these effects, and no long-term human data at all. The theoretical concern of chronic supraphysiologic GH (insulin resistance, acromegaly-like changes) is unmeasured for ipamorelin.

Often stacked with CJC-1295 — effects can be additive. Because CJC-1295 raises GH through a different lever (more GHRH signal), pairing it with ipamorelin can amplify the shared GH-axis effects like water retention. See CJC-1295 side effects.

A single small clear glass vial of fine white lyophilized peptide powder on a cool-grey laboratory bench beside a sterile unbranded fine-gauge syringe and an amber vial of bacteriostatic water under soft studio lighting.

What are the most common ipamorelin side effects?

Across 450 ProtocolPlus users who tracked ipamorelin tolerability, the most-reported effects are a mild injection-site reaction (14%), a brief head-rush or flushing (10%), mild water retention (9%), numbness or tingling (8%), and headache (8%) — almost all self-reported as mild, transient, and clustered early in a cycle. This is a community-report ranking from our own app data, not a validated incidence table, because no such table exists for ipamorelin.

The shape of the list is exactly what its mechanism predicts, and it is the quiet evidence for the "cleaner GHRP" reputation. As a selective growth-hormone secretagogue, ipamorelin produces a GH pulse with very little off-target stimulation, so the harsher GHRP complaints are muted: increased hunger sits at just 6% (27 users) here, where a strong ghrelin-receptor agonist like GHRP-6 is notorious for ravenous appetite. After the top cluster, reports tail off into milder, less specific complaints: fatigue (7%, 32 users), dizziness (5%, 22), joint aches (5%, 22), and vivid dreams (4%, 18). In our dataset, eight of the ten reported effects were tagged mild and two moderate (water retention and tingling); none were severe.

Read that carefully, though, because it is easy to over-read. These shares come only from our community-reported dataset and describe what people experience and log, not trial-grade incidence and not causation. A short, mild list from a self-selected group is consistent with ipamorelin being well-tolerated — but it is equally consistent with under-reporting, short follow-up, and a healthy-user effect. The mechanism behind each effect lives on the hub; for the molecule itself see the Ipamorelin complete guide.

Citation capsule. Among 450 ProtocolPlus users who tracked ipamorelin tolerability, the most-reported effects were an injection-site reaction (14%, 63 users), head-rush/flushing (10%, 45), water retention (9%, 40, moderate), numbness/tingling (8%, 36, moderate), and headache (8%, 36); increased hunger was notably milder (6%, 27) than older GHRPs cause. Every reported effect was mild or moderate, none severe. This is first-party data reflecting what the community reports — self-reported, not validated trial incidence, and not proof of causation. Ipamorelin has no completed human safety trials. Source: ProtocolPlus app data (side-effects/ipamorelin.json), 2026.

The moat — and its limit: what 450 ProtocolPlus users report for ipamorelin, severity-colored. Note how small the hunger bar is (the "clean GHRP" signature). Everything reported is mild-to-moderate, with no severe events. But this is a self-reported signal, not validated incidence: ipamorelin has never been through a human safety trial.

What does ipamorelin safety actually look like — and what don't we know?

The honest answer is that ipamorelin's safety picture is mostly a blank page: it is reported as well-tolerated and is genuinely the most selective GHRP, but there are no completed human safety trials, no validated incidence, and no long-term human data — so the most important "side effects" are the ones nobody has measured yet. This is the part the clinic and vendor pages skip, and it is the part that actually matters.

For an approved drug, you can open the label and read a validated adverse-event table from a controlled trial. Ipamorelin has nothing like that. Its furthest clinical development was a Phase 2 trial for postoperative ileus that was discontinued for lack of efficacy, not a completed safety program — so the human record is essentially that one abandoned program plus uncontrolled community reports like ours. Instead of a long list of documented severe reactions, the right "red flag" block for ipamorelin is a list of known unknowns.

⚠ WHAT WE DON'T KNOW — the real safety gaps (unknowns, not documented harms)

No human safety trial, no incidence

Unknown — not studied

The gap: ipamorelin's furthest development was a Phase 2 ileus trial stopped for lack of efficacy. No completed safety trial means no validated side-effect rate for anything.

Why it matters: our 14% injection-site figure is a community report, not an incidence; "cleaner GHRP" is mechanistic, not safety-validated.

Theoretical GH-excess effects

Hypothesis — not documented for ipamorelin

The gap: chronically raising growth hormone is what causes acromegaly's problems — insulin resistance, higher blood glucose, and over years, acromegaly-like tissue changes.

Why it matters: the GH pulses these peptides produce are smaller, but no one has measured chronic supraphysiologic GHRP use in people, so treat it as caution, not a proven risk.

Product quality, not the peptide

The most concrete real-world risk

The gap: unregulated "research only" vials can carry endotoxins, the wrong peptide, residual solvents, or mislabeled doses; at-home reconstitution adds infection risk.

Why it matters: the documented real-world harms cluster here, not in ipamorelin's known pharmacology.

None of the above is a documented severe adverse event reported by our community — these are open questions and theoretical concerns, framed honestly as unknowns. If you ever develop signs of infection at an injection site (spreading redness, warmth, pus, fever), severe swelling, chest pain, or any severe or persistent symptom, stop and see a clinician — that is true for any injectable.

Citation capsule. Ipamorelin has no completed human safety trials; its furthest development was a Phase 2 trial for postoperative ileus discontinued for lack of efficacy, so no validated incidence exists. The theoretical long-term concern is GH excess: chronic growth-hormone overproduction (as in acromegaly) drives insulin resistance, glucose intolerance, and ultimately diabetes — a mechanistic basis for caution with chronic supraphysiologic GH-secretagogue use, not a documented ipamorelin harm. The most concrete real-world risk comes from contamination and mislabeling of unregulated product. Sources: ClinicalTrials.gov NCT00672074 (Helsinn, 2008); Frontiers in Endocrinology (Vila et al., "Insulin Resistance in Patients With Acromegaly"), 2019.

What do the reported ipamorelin side effects feel like, and how does the community handle them?

The reported effects are mostly mild and short-lived — an injection-site reaction is the standout, then a brief head-rush, with the growth-hormone-axis cluster (mild water retention, tingling, joint aches) and a notably gentler hunger bump than other GHRPs. Below is each commonly reported effect: what it feels like, when it tends to show up, and how the community tends to handle it. These are descriptions of common practice, not a prescription — dose decisions belong with a clinician, and for how cycles are typically structured the CJC-1295 + Ipamorelin dosage calculator lays out the reported ranges.

Injection-site reaction (14%, 63 users)

By far the most-reported effect, and the most expected one for any subcutaneous injectable: mild redness, stinging, or a small bump at the site. It is local, not systemic, and usually fades within hours to a day. Community practice is standard injection hygiene — clean technique, rotating sites, letting reconstituted solution come to room temperature, and using a fresh fine-gauge needle each time. A normal injection-site reaction is not the same as an infection; spreading redness, warmth, swelling, or fever is the line that turns "expected" into "see a clinician."

Head-rush and flushing (10%, 45 users)

The signature "I just dosed" sensation with GHRPs: a brief warm flush, a light-headed head-rush, sometimes a flushed face, in the minutes after injection. It is typically transient and tied to the acute GH pulse and short-term vasodilation. Community practice is to dose seated or before bed, stay hydrated, and not stand up too quickly right after — and to treat anything beyond a brief flush (a pounding headache, chest tightness) as a reason to stop and reassess rather than redose.

Water retention (9%, 40 users) — the GH-axis signature

This is the most characteristic growth-hormone effect on the list, and the reason it is tagged moderate. Raising GH causes the body to hold fluid, which shows up as mild puffiness — often in the hands, ankles, or face — and a small, fast scale bump that is water, not fat or muscle. This is the same fluid-retention effect listed on every somatropin (recombinant GH) label, just usually milder at the pulses a peptide produces. It is typically dose-dependent and tends to ease if the dose is lowered. Community practice is watching sodium and hydration, not chasing the scale day-to-day, and easing the dose if puffiness is bothersome — and importantly, this is the effect most likely to be amplified by stacking with CJC-1295, which pushes GH up through a second lever (see CJC-1295 side effects).

Tagged moderate and worth understanding because it usually comes from the water retention above, not from the peptide acting on nerves directly. When GH-driven fluid accumulates, it can press on nerves — classically a carpal-tunnel-like tingling or numbness in the hands and fingers. On GH therapy this is a recognized, usually transient and dose-dependent class effect. The community handling is the same as for water retention: it often tracks the dose, so easing back tends to settle it. Persistent or worsening numbness is a reason to stop and check with a clinician.

The milder hunger (6%, 27 users) — vs other GHRPs

This is the column that earns ipamorelin its reputation. Older GHRPs such as GHRP-6 are strong ghrelin-receptor agonists and famously trigger intense hunger; ipamorelin's selectivity means it does this far less, which is why increased hunger sits low on our list at 6%. It is genuinely a tolerability advantage for anyone using a GH peptide while trying to manage body composition — but "milder than GHRP-6" is not "none," and a minority of users still notice an appetite bump, usually mild and dose-related.

The milder tail (headache 8%, fatigue 7%, dizziness 5%, joint aches 5%, vivid dreams 4%)

Headache (36 users) and dizziness (22) often track with the post-dose head-rush and fluid shifts and tend to be brief. Fatigue (32) is non-specific and usually early-cycle. Joint aches (22) are another recognized GH-axis effect (arthralgia from fluid retention), generally mild here. Vivid dreams (18) are commonly reported with GH-axis peptides taken before sleep and are usually described as harmless, sometimes even welcome. None of these were tagged severe in our dataset, and the community approach is unremarkable: hydration, dosing timing, and pausing to reassess anything persistent rather than fleeting.

When do effects start and ease? (the time-course)

The pattern most people describe is front-loaded and dose-linked: the head-rush is immediate and brief, while the fluid-retention cluster (water retention, tingling, joint aches) tends to appear in the first days to weeks and ease if the dose is held or lowered, mirroring how GH-therapy fluid effects behave on a label. That said, this is exactly where the data gap bites — because there is no long-term human study, we genuinely do not know whether a clean first few weeks predicts a clean few months. The community convention is to run defined cycles rather than open-ended use, which is a reasonable risk-limiting habit, but it is a convention, not a safety-validated protocol.

A macro close-up of a person's hands gently pressing slightly puffy fingers and the back of one hand, showing subtle mild fluid retention around the knuckles and wrist in soft natural light, illustrating mild GH-related water retention.

Our take: The single most useful safety habit with ipamorelin is changing one variable at a time. Because nothing here has a validated cause-and-effect profile, the only way to know whether the peptide caused a symptom — versus your sleep, a stacked compound like CJC-1295, or the product itself — is to not start three things at once. Go slow, run one compound, watch the water-retention cluster as your dose signal, and treat any sign of infection or anything cardiovascular as a stop signal.

Is ipamorelin really the "cleanest" GHRP? (the comparison, honestly)

Yes, ipamorelin is genuinely the most selective GHRP — in the 1998 discovery study it released growth hormone as potently as GHRP-6 but, unlike GHRP-6 and GHRP-2, did not significantly raise ACTH, cortisol, or prolactin, and it stimulates appetite far less — but "cleanest" is a comparison to harsher peptides, not a clean bill of health. This is the claim every competitor page repeats without a source; here is where it actually comes from, and where it stops.

The selectivity is real and well-documented. In Raun et al. (1998), the paper that literally named ipamorelin "the first selective growth hormone secretagogue," it matched GHRP-6 on GH release yet did not release ACTH or cortisol at levels different from plain GHRH stimulation — even at doses far above the GH threshold — and did not move prolactin. By contrast, GHRP-6 and GHRP-2 co-release cortisol and prolactin, and GHRP-6 in particular is a potent appetite stimulant. So three of the four things people dislike about older GHRPs (cortisol spikes, prolactin, ravenous hunger) really are muted with ipamorelin. That is a genuine tolerability win, and it is why our hunger column is small.

Here is the honest boundary, though. "Cleaner on the off-target axes" does not mean "free of the on-target ones." Everything ipamorelin does flows from raising growth hormone, so it keeps the entire GH-axis cluster — water retention, the fluid-driven tingling and joint aches — that any GH secretagogue shares, because those come from the GH itself, not from cortisol or prolactin. And selectivity says nothing about the two biggest safety facts on this page: there is still no validated human incidence, and there is still no long-term data. The comparison below is therefore "ipamorelin vs other GHRPs on the off-target axes" — not "ipamorelin vs proven safe."

Axis	Ipamorelin	GHRP-6 / GHRP-2	What it means
GH release	Strong (≈ GHRP-6)	Strong	The intended effect — shared
Cortisol / ACTH	Not significantly raised	Raised	Ipamorelin "cleaner"
Prolactin	Not raised	Raised	Ipamorelin "cleaner"
Appetite / hunger	Mild (6% here)	Strong (GHRP-6 notably orexigenic)	Ipamorelin "cleaner"
GH-axis fluid effects (water retention, tingling, joint aches)	Present (shared)	Present (shared)	NOT cleaner — comes from GH itself
Validated human safety	None	None	Neither is proven safe

The differentiator visual: ipamorelin matches GHRP-6/GHRP-2 on GH release but is far lower on cortisol, prolactin, and appetite — the basis for its "cleanest GHRP" reputation. Directional from Raun 1998, not invented percentages. Note this chart says nothing about the shared GH-axis fluid effects or about long-term safety.

Is ipamorelin legal and FDA-approved?

Ipamorelin is not FDA-approved for any use, it is sold only "for research use only," and it is banned in sport (WADA class S2) — its regulatory history reflects exactly the data gap this page is about. This is a safety-relevant point, not a footnote.

Ipamorelin's furthest clinical development was a Phase 2 trial for postoperative ileus that was discontinued for lack of efficacy; it was never approved as a medicine, and today it is sold as an unapproved research chemical. Its compounding status has bounced: the FDA placed ipamorelin in Category 2 ("significant safety risks") of its interim 503A bulk-substances list in September 2023, then removed it in September 2024 after the nomination was withdrawn — a regulatory and supply-chain decision, not a verdict that its safety questions were answered. Separately, as a growth-hormone secretagogue, ipamorelin sits on the World Anti-Doping Agency Prohibited List (class S2, peptide hormones and growth factors) alongside the other GHRPs, so it is banned at all times for tested athletes and would cause a positive test. For the full legal and status picture, the Ipamorelin complete guide keeps the up-to-date regulatory detail.

Citation capsule. Ipamorelin is an unapproved drug, not FDA-approved for any condition, and sold "for research use only." Its furthest development was a Phase 2 ileus trial discontinued for lack of efficacy. The FDA added it to the 503A interim bulk-substances list as Category 2 ("significant safety risks") in September 2023 and removed it in September 2024 after the nomination was withdrawn. As a growth-hormone secretagogue it is on the WADA Prohibited List, class S2 (banned at all times). Sources: ClinicalTrials.gov NCT00672074; FDA 503A bulk drug substances actions (2023–2024); WADA 2026 Prohibited List, S2.

Who should be especially cautious with ipamorelin?

Because ipamorelin has no validated human safety data, the cautious default is "not without a clinician" — and the caution is sharper for anyone with diabetes or blood-sugar issues (given the theoretical GH-to-insulin-resistance link), anyone pregnant or trying to conceive, anyone with a cancer history, and tested athletes. These are not contraindications established by a label, because no label exists; they follow from the mechanism and the missing data.

A few practical lines follow. Because growth hormone opposes insulin, anyone with diabetes, prediabetes, or glucose concerns should treat the theoretical blood-sugar effect as a real reason to involve a clinician and monitor, especially with chronic use. Pregnancy and fertility are simply unstudied in humans, which means "avoid" is the conservative call. Because GH and IGF-1 are growth signals, a cancer history is worth discussing with an oncologist before considering any GH secretagogue. Tested athletes should know it is a WADA S2 ban. And because the research-grade ("for research use only") product is unregulated, product quality is its own caution on top of the molecule — for how to think about sourcing and third-party testing, see how to vet peptide quality. None of this page replaces a clinician conversation; with an investigational compound, that conversation matters more, not less.

Frequently Asked Questions

Among 450 ProtocolPlus users who tracked tolerability, the most-reported effects were a mild injection-site reaction (14%), a head-rush or flushing (10%), mild water retention (9%), numbness or tingling (8%), and headache (8%), with increased hunger notably milder (6%) than older GHRPs. Every reported effect was mild or moderate; none were severe. This is self-reported community data, not validated trial incidence — ipamorelin has no completed human safety trials, so no validated side-effect rate exists.

The bottom line

If you came here asking whether ipamorelin is "safe," the honest answer has two layers you need to hold at the same time. The first is reassuring, and the "cleanest GHRP" reputation is earned: ipamorelin really is the most selective of its class — far less cortisol, prolactin, and hunger than GHRP-6 or GHRP-2 — and our 450 community users mostly report nothing or report mild, short-lived effects: a sting at the injection site, a brief head-rush, some mild water retention. Nobody in our community-reported set logged a severe event.

The second layer is the one the clinic and vendor pages bury, so we will not: "cleaner than other GHRPs" is not the same as proven safe. Ipamorelin still carries the shared growth-hormone-axis cluster — water retention, the fluid-driven tingling and joint aches — because those come from the GH itself, not from the off-target effects it avoids. And it has never completed a human safety trial, so there is no validated side-effect rate and no long-term human data, plus a theoretical GH-excess concern for chronic use. Use that framing to make a clear-eyed decision with a clinician, change one variable at a time, watch the water-retention cluster as your dose signal, and remember the most concrete real-world risk is often the unregulated product itself. From here, the natural next reads are the Ipamorelin complete guide for the molecule and the science, the CJC-1295 + Ipamorelin dosage calculator for how cycles are reported, and CJC-1295 side effects since the two are so often stacked.

Sources

Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998;139(5):552-561. Retrieved 2026-06-18. https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390
Lawrence CB, Snape AC, Baudoin FM-H, Luckman SM. "Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers." Endocrinology, 2002;143(1):155-162. Retrieved 2026-06-18. https://pubmed.ncbi.nlm.nih.gov/11751604/
U.S. Food & Drug Administration. "Genotropin (somatropin) — Prescribing Information" (Warnings & Precautions: fluid retention, edema, arthralgia, carpal tunnel syndrome/paresthesias; dose-dependent, transient). 2024. Retrieved 2026-06-18. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021426s043lbl.pdf
Vila G, Jørgensen JOL, Luger A, Stalla GK. "Insulin Resistance in Patients With Acromegaly." Frontiers in Endocrinology, 2019;10:509. Retrieved 2026-06-18. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00509/full
ClinicalTrials.gov. "Safety and Efficacy of Ipamorelin for the Management of Postoperative Ileus" (NCT00672074, Helsinn Therapeutics, Phase 2; discontinued). Retrieved 2026-06-18. https://clinicaltrials.gov/study/NCT00672074
U.S. Food & Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act" (ipamorelin interim Category 2, Sept 2023; removed Sept 2024 after nomination withdrawn). Retrieved 2026-06-18. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
World Anti-Doping Agency. "The 2026 Prohibited List" (Section S2.2.4, Growth Hormone secretagogues / GH-releasing peptides — ipamorelin named; prohibited at all times). 2026. Retrieved 2026-06-18. https://www.wada-ama.org/en/prohibited-list
ProtocolPlus. "Community-reported tolerability data: ipamorelin" (side-effects/ipamorelin.json). First-party app data, 2026. N = 450 users who tracked ipamorelin tolerability. Self-reported community frequency, not validated incidence and not proof of causation.